ERGO (Entia Biosciences) ROCE %: 0.00% (As of Dec. 2016)


What is Entia Biosciences ROCE %?

Entia Biosciences ERGO ROCE % is 0.00% as of Dec. 2016.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Entia Biosciences's annualized ROCE % for the quarter that ended in Dec. 2016 was 0.00%.

Entia Biosciences  (OTCPK:ERGO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Entia Biosciences ROCE % Related Terms

Entia Biosciences ROCE % Historical Data

* Premium members only.

The historical data trend for Entia Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entia Biosciences ROCE % Chart

Entia Biosciences Annual Data
Trend Jul07 Jul08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entia Biosciences Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entia Biosciences ROCE % Calculation

Entia Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2016 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2016 )  (A: Dec. 2015 )(A: Dec. 2016 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2016 )  (A: Dec. 2015 )(A: Dec. 2016 )
=-1.312/( ( (0.449 - 1.24) + (0.439 - 2.106) )/ 2 )
=-1.312/( (-0.791+-1.667)/ 2 )
=-1.312/-1.229
=106.75 %

Entia Biosciences's ROCE % of for the quarter that ended in Dec. 2016 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2016 )  (Q: Sep. 2016 )(Q: Dec. 2016 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2016 )  (Q: Sep. 2016 )(Q: Dec. 2016 )
=-1.556/( ( (0.366 - 1.711) + (0.439 - 2.106) )/ 2 )
=-1.556/( ( -1.345 + -1.667 )/ 2 )
=-1.556/-1.506
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2016) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Entia Biosciences (ERGO) has a ROCE % of 0.00% as of Dec. 2016.
Is Entia Biosciences' ROCE % too high?
Entia Biosciences' current ROCE % is 0.00%.
How does Entia Biosciences' ROCE % compare to OBMP and NSPX?
Entia Biosciences' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Entia Biosciences's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entia Biosciences stock overvalued right now?
Entia Biosciences (ERGO) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Entia Biosciences (ERGO), the current ROCE % is 0.00% as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entia Biosciences Business Description

Address 13565 South West Tualatin-Sherwood Road, Suite 800, Sherwood, OR, USA, 97140
Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.